CORRESP Filing
Enlivex Ltd.
Date: Dec. 30, 2025 · CIK: 0001596812 · Accession: 0001213900-25-126361
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292417
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Jimmy McNamara RE: Enlivex Therapeutics Ltd. (the "Company") Registration Statement on Form F-3 (the "Registration Statement") Filed December 23, 2025 File No. 333-292417
Dear Mr. McNamara:
The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 4:00 p.m. on January 2, 2026, or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
Enlivex Therapeutics Ltd .
Show Raw Text
CORRESP 1 filename1.htm Enlivex Therapeutics Ltd. 14 Einstein Street Ness Ziona Israel 7403618 December 30, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attention: Jimmy McNamara RE: Enlivex Therapeutics Ltd. (the "Company") Registration Statement on Form F-3 (the "Registration Statement") Filed December 23, 2025 File No. 333-292417 Dear Mr. McNamara: The Company hereby requests, pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, acceleration of effectiveness of the Registration Statement so that such Registration Statement will become effective as of 4:00 p.m. on January 2, 2026, or as soon thereafter as practicable. [Signature page follows] Very truly yours, Enlivex Therapeutics Ltd . By: /s/ Oren Hershkovitz Name: Oren Hershkovitz Title: Chief Executive Officer